Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
Loading...
Date
Authors
Florentin, M.
Liberopoulos, E. N.
Mikhailidis, D. P.
Elisaf, M. S.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Expert Opin Pharmacother
Book name
Book series
Book edition
Alternative title / Subtitle
Description
BACKGROUND: Sitagliptin is a novel agent for the treatment of type 2 diabetes either as monotherapy or in combination with metformin or a thiazolidinedione. OBJECTIVE: To review the efficacy and safety of sitagliptin in clinical trials and comment on drug interactions and safety issues arising from its use. METHODS: Relevant articles were identified through a PubMed search (up to May 2008). RESULTS/CONCLUSIONS: Sitagliptin either used alone or in combination with other hypoglycemic agents has a favorable glucose-lowering effect and safety profile. It has been associated with few side effects, mainly involving the gastrointestinal system and with a low incidence of hypoglycemia, while it generally demonstrated a neutral effect on body weight. Sitagliptin is a safe alternative or complementary option for patients with type 2 diabetes who do not reach the recommended glycosylated hemoglobin level with lifestyle interventions and/or current oral antidiabetic agents.
Description
Keywords
Adult, Aged, Blood Pressure/drug effects, Child, Clinical Trials as Topic, Diabetes Mellitus, Type 2/*drug therapy, Dipeptidyl-Peptidase IV Inhibitors/therapeutic use, Drug Interactions, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use, Lipids/blood, Male, Pregnancy, Pyrazines/administration & dosage/adverse effects/*therapeutic use, Triazoles/administration & dosage/adverse effects/*therapeutic use
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/18570604
http://informahealthcare.com/doi/abs/10.1517/14656566.9.10.1705
http://informahealthcare.com/doi/abs/10.1517/14656566.9.10.1705
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής